Eugene C. Butcher
Corporate Officer/Principal chez Stanford University
Profil
Eugene C.
Butcher is a Director of BioSeek, Inc. Dr. Butcher is a Professor in the Department of Pathology at Stanford University and a Staff Physician at the Veterans Affairs Palo Alto Health Care System.
He was Scientific Co-Founder and Co-Chair of the Scientific Advisory Board of Leukosite, Inc. (now merged with Millennium Pharmaceuticals).
Dr. Butcher was a Director of Millennium, Medimmune, and Thios Pharmaceuticals.
He received a BS from the Massachusetts Institute of Technology and an MD from from the Washington University School of Medicine.
Postes actifs de Eugene C. Butcher
| Sociétés | Poste | Début |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
Anciens postes connus de Eugene C. Butcher
| Sociétés | Poste | Fin |
|---|---|---|
Thios Pharmaceuticals, Inc.
 Thios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thios Pharmaceuticals, Inc. was engaged in providing researches therapies. The therapies provided by the company target sulfation pathways, which could lead to potential for treatments for inflammation, cancer and other diseases. Thios Pharmaceuticals was located in Oakland, CA. | Directeur/Membre du Conseil | - |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Président | - |
Millennium Ventures Ltd.
 Millennium Ventures Ltd. Financial ConglomeratesFinance Millennium Ventures Ltd. operates as an investment firm. The company is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - |
BioSeek, Inc.
 BioSeek, Inc. Miscellaneous Commercial ServicesCommercial Services BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. | Fondateur | - |
Formation de Eugene C. Butcher
| Massachusetts Institute of Technology | Undergraduate Degree |
| Washington University in St. Louis | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
BioSeek, Inc.
BioSeek, Inc. Miscellaneous Commercial ServicesCommercial Services BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. | Commercial Services |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Millennium Ventures Ltd.
Millennium Ventures Ltd. Financial ConglomeratesFinance Millennium Ventures Ltd. operates as an investment firm. The company is headquartered in Vancouver, Canada. | Finance |
Thios Pharmaceuticals, Inc.
Thios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thios Pharmaceuticals, Inc. was engaged in providing researches therapies. The therapies provided by the company target sulfation pathways, which could lead to potential for treatments for inflammation, cancer and other diseases. Thios Pharmaceuticals was located in Oakland, CA. | Health Technology |